Jonathan Javitt

Jonathan Javitt

Chief Executive Officer, Chief Scientist and ChairmanatNRX Pharmaceuticals· In proxies 2023–2024

Pay in FY2024+31% from the year before · NRX Pharmaceuticals stock -52.2% the same year

Jonathan Javitt was paid $825.0K in FY2024 (Dec), up 31%. NRX Pharmaceuticals stock fell 52.2% that year.

Pay$100 in the stock at the end of FY22 → $20
Pay is from the Summary Compensation Table of each NRX Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. NRX PharmaceuticalsPublic company · 3 yr
    • Chief Executive Officer, Chief Scientist and Chairman2023 – Present · 3 yrStock in role -76%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?